Bayer's two-year data confirm eeylea's effectiveness

Bayer released two years of data that confirmed the use of active treatment and prolongation (T-E) Eylea solution in patients with wet age-related macular degeneration (wet AMD), which is the main cause of vision loss.
The in vivo injection data came from the IIIb/IV ARIES study, and further results came from indirect comparisons of published randomized clinical trials of wet AMD antivascular endostroin growth factor therapy fibers or ranibizumab.
Data show that more than half of patients extend the injection interval to 12 weeks or more, and by week 104, up to one-third of patients extend to 16 weeks of injection interval.
Dr Jackie Napier, medical director of Bayer Ophthalmology, said: "Treatment of wet AMD has a profound impact on the ability of the NHS to be over-stressed and on the lives of people with the disease and their carers."
The data are important because they once again confirm the evidence available for proactive T-E therapies and offer clinicians the possibility of reducing the number of injections needed to save vision," she continued.
for some patients, this may result in only three injections in the second year of treatment, which may reduce some service stress and the burden on patients associated with treatment. Wet
is a serious and debilitating vision-threatening disease that requires ongoing treatment to prevent symptoms from worsening, with around 39,800 new cases diagnosed in the UK each year.
Under the treatment and extension programme, after setting an initial dose, clinicians can adjust the treatment plan to the individual needs of each patient by gradually extending or shortening the injection interval, depending on the patient's disease activity. (cyy123.com)